EHA 2020 | ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL

Jeffrey Lancet, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reports results from a Phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).